Boundless Bio, Inc. (BOLD) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
9880 Campus Point Drive
San Diego, CA 92121
United States of America (the)
Phone
858 766 9912
Website
Sector
Healthcare
Industry
Biotechnology
Employees
64
First IPO Date
July 20, 2016
| Name | Title | Pay | Year Born |
| Zachary Hornby | Chief Executive Officer, President & Director | 974,855 | 1979 |
| Christian Hassig | Chief Scientific Officer | 673,000 | 1972 |
| Robert C. Doebele | Chief Medical Officer | 690,275 | 1971 |
| James L. Freddo | Interim Chief Medical Officer | 0 | 1955 |
| Amy Berkley | Senior Vice President of Program Team | 0 | N/A |
| Jessica Oien | Chief Legal Officer & Corporate Secretary | 0 | 1971 |
| Meredith Wesley | Chief Human Resources Officer | 0 | N/A |
| David Hinkle | Senior Vice President of Finance, Controller & Corporate Treasurer | 0 | 1962 |
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.